NICE issues positive recommendation for Tagrisso in early-stage lung cancer

UK pharma major AstraZeneca (LSE: AZN) today announced that Tagrisso (osimertinib) is now available as an adjuvant treatment option after complete tumor resection in adult patients in England with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations via the Cancer Drugs Fund (CDF).

Treatment with osimertinib is subject to a three-year clinical stopping rule. This follows a positive final recommendation from the National Institute for Health and Care Excellence (NICE)

In September last year, the UK’s reimbursement agency provided a positive decision on AstraZeneca’s Tagrisso for certain people with locally-advanced or metastatic non-small cell lung cancer (NSCLC). Already one of the company’s top-selling drugs, Tagrisso notched up sales of $1.2 billion in the third quarter of this year, a year-on-year rise of 8%.